Treatment of Patients With Diffuse Large B-cell Non-Hodgkins Lymphoma in Stages I and II Without Risk Factors, Adapted to the Response Evaluated With PET CT (Positron Emission Computed Tomography)
Sponsor study identifier
observational
75
1 country
7
Study Start
June 1, 2021
Actual (reported)Primary Completion
June 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Prospective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 1, 2021
Actual (reported)September 21, 2021
Actual (reported)October 15, 2021
Actual (reported)June 1, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Evaluate PFS in patients with stage I and II LBCL (large B cell lymphoma), without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP.
36 months
Evaluate OS in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
36 months
Evaluate PFS in patients with negative PET after 3rd cycle who shortened treatment to only 4 cycles of R-CHOP.
36 months
Evaluate PFS in patients with positive PET after 3rd cycle who continue treatment with R-CHOP x 1 and Radiotherapy.
36 months
Evaluate the prognostic value of baseline MTV (metabolic tumor volume) in patients with DLBCL under treatment adapted to response after 3 cycles of R-CHOP
36 months
Evaluate the prognostic value of baseline TLG (total lesion glycolysis) in patients with DLBCL under treatment adapted to response after 3 cycles of R-CHOP
36 months
Evaluate the prognostic value of Δ SUV (standardized uptake value) max in interim PET in patients with DLBCL under treatment adapted to response after 3 cycles of R-CHOP
36 months
Patients with DLBCL in limited stages and without risk factors that will receive standard chemoimmunotherapy and their treatment will be adapted according to PET response after 3 cycles.
Evaluation of first line treatment in patients with stage I and II LBCL, without poor prognostic factors with treatment adapted to PET-CT after 3 R-CHOP
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adult patients with recent diagnosis of DLBCL in limited stages without risk factors and no previous history of mliagnant disease.
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Instituto Privado de Hematologia y Hemoterapia
Paraná, Entre Ríos Province, Argentina
IDHEA Clínica Hematológica
Rosario, Santa Fe Province, Argentina
Amalia Cerutti, Dr.
Grupo Argentino de Tratamiento de la Leucemia Aguda
Astrid Pavlovsky, Dr.
Grupo Argentino de Tratamiento de la Leucemia Aguda
First Submitted
September 21, 2021
First Posted
October 15, 2021
Study Start
June 1, 2021
Actual (reported)Primary Completion
June 1, 2024
Estimated (date passed)Contact the study team to confirm eligibility.
FUNDALEU
CABA, Argentina
Hospital Italiano de Buenos Aires
CABA, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, Argentina
Hospital Privado de Córdoba
Córdoba, Argentina
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 1, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 9, 2024
Record last verified: 2024-01
Share study protocol
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: